SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (11260)7/12/1998 7:44:00 AM
From: EyeDrMike  Read Replies (1) | Respond to of 23519
 
Was told 4 lines currently up and running at the new plant.

Mike



To: DaiS who wrote (11260)7/12/1998 10:50:00 AM
From: ChinuSFO  Read Replies (1) | Respond to of 23519
 
DaiS, is it possible that in the UK the doctors could be gently persuaded to use the taxpayers' money prudently and recommend to people who are in clinical need of a ED drug, to use MUSE even though its administration is relatively unpalatable compared to Viagra. That would keep the blackmarketeers at bay.

Just a dream, is it not.



To: DaiS who wrote (11260)7/12/1998 11:52:00 AM
From: Mkilloran  Respond to of 23519
 
dias...thanks for the UK update..the rules will be different in the UK and other countries IMO....the USA Viargra rollout has taught these other countries that there is a need to screen patients for Viagra better.

Muse will hold a better percent of the ed population in these countries as a result of this and better marketing by Astra and Janssen.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News